Received Oct 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MEN | MENINGOCOCCAL (NO BRAND NAME) | UNKNOWN MANUFACTURER | 1 | U8493AA | OT / LA |
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | — | OT / RA |
| MEN | MENINGOCOCCAL (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | U8493AA | IM / LA |
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | UNK | — |
received MENQUADFI and Menveo, both meningococcal A, C, W, Y conjugate vaccines, on the same day with no reported AE; This non-serious case was reported by a other health professional via other manufacturer and described the occurrence of overdose in a 17-year-old male patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis. Co-suspect products included Meningococcal vaccine A/C/Y/W conj (tet tox) (Menquadfi) (batch number U8493AA, expiry date 30-MAY-2028) for prophylaxis. On 22-SEP-2025, the patient received Menveo and Menquadfi (intramuscular, left arm) .5 ml. On 22-SEP-2025, an unknown time after receiving Menveo and Menquadfi, the patient experienced overdose (Verbatim: received MENQUADFI and Menveo, both meningococcal A, C, W, Y conjugate vaccines, on the same day with no reported AE). The outcome of the overdose was not applicable. Additional Information: GSK Receipt Date:13-OCT-2025 The patient had not reported any adverse reaction.